-1. Sketch how mongersen is expected to increases anti-inflammatory cell signaling. (10%) Since gut inflammation of Crohn’s disease is characterized by abnormal decreases in the activity of the immunosuppressive cytokine transforming growth factor (TGF)–β1, which is induced by the increased level of SMAD7 protein, because it would prevent TGF-β1–associated and SMAD-associated signaling.[1] The formulation of Mongersen (formerly GED-0301) contains a 21-base single-strand phosphorothioate oligonucleotide, which would hybridize to the human SMAD7 messenger RNA (mRNA) complementary and then facilitate RNase H–mediated RNA degradation[1], thus it would reduce the translation product and help maintain the level of SMAD7 protein in the normal range. -2. Find the structure of mongersen: --what is the “backbone” of mongersen? (5%) Mongersen is a 21-base phosphorothioate oligonucleotide with the sequence 5′-GTC GCC CCT TCT CCC CGC AGC-3′.[1] The nonbonding oxygen in each internucleotide linkage of phosphodiesters is replaced by a sulfur atom(shows as Fig1). Also, the cytosine residues at nucleotide positions 3 and 16 are modified by 5-methylation.[1] Fig 1. The difference between phosphodiester linkage and phosphorothioate linkage. --why might the developers have chosen this backbone over other possibilities for antisense or siRNA molecules? (5%) The oligonucleotide antisense matches complementary to the region 107–128 of the human Smad7 mRNA sequence, and its
Crohn’s disease (CD) is a systemic auto-immune disease that is marked by abnormal inflammation of the gastrointestinal (GI) tract, it affects any part of the GI tract from mouth to anus. CD mainly presents in three areas: the small intestine, the colon, and the perianal region. CD mostly occurs between the ages of 15 and 30 years, or between the ages of 60 and 80 years of age. The exact etiology of Crohn’s disease is unknown. As stated by Mazal (2014) “Genetic predisposition—especially familial aggregation—seems to be the strongest independent indicator of which individuals will develop Crohn disease” (p.298). An increase diet in milk protein, milk protein and polysturated fatty acids is also a possible factor in disease incidences. Smoking may also double the risk of developing CD.
1. Arrange the following molecules from least to most specific with respect to the original nucleotide sequence: RNA, DNA, Amino Acid, Protein
D1S80 locus is placed on the short arm of the chromosome 1. This locus does not code for the arrangement for protein, yet it codes for a series of tandem repeats of 16 bp in human. Distinctive number of this allele has different number of repeats. These quantities of repeats are exceptional to every human. Primer
bonds and taking a glucose molecule off of the structure (Ball, Vialle, Alonso-Casajus, Duavillee, Munoz, Baroja-Fernandez, Moran-Zorzano, Eydallin, Pozueta-Romero, 2006). The conditions for the reaction of Phosphorylase and
There is no "cure" for Crohn's disease, but medical therapy with one or more drugs provides a means to treat early Crohn's disease and relieve its symptoms. The most common drugs prescribed are corticosteroids, such as prednisone and methylprednisolone, and various anti-inflammatory agents. The main treatment for Crohn's disease is medicine to stop the inflammation in the intestine and medicine to prevent flare-ups and keep the individual in remission. Treatment may include medications, surgery, nutrition supplementation, or a combination of these options; these are some of the medications used in the treatment: Anti-inflammation medications, Cortisone or steroids, Immune system
In this PCR mixture you can find Taq polymerase, dNTPs, primers, MgCL2, buffer, and water. One of the primers altered the sequence of the DNA. In the sequence, one of the Adenine bases was changed to a Guanine. This
Second, in order to further confirm the information about characteristics and function of the targeting protein that we have
This review will explain Crohn’s disease and Ulcerative colitis, two types of inflammatory bowel disease that affect millions of people. These diseases are chronic that affects certain parts of the intestine gastrointestinal tract. People who has this disease are troubled with a variety of side effects that they will have to live with for the rest of their lives. To this day, there are no medical cure for these diseases, however there are several treatment options that are helpful. These diseases are still being studied for researchers to fully understand the causes, possible preventions, and cure for IBDs. Countless researches and studies are still under development, there have been many discoveries thus far, but nothing concrete.
This prevents the release of the inflammatory factors which cause Crohn’s disease; however it also prevents the intended effects of the cell, such as inducing cell apoptosis, and inhibiting viral replication. Due to these side effects, anti-TNF-α treatment can result in an increased risk of cancer, infection and fungal infections. Furthermore, although effective in most patients, 30% of people who receive this treatment do not respond and continue to show symptoms from Crohn’s [6]. This suggests that TNF-α is not the only cause of the disease, adding to the complexity of the
Crohn’s Disease is an intestinal disease first discovered by and named after Dr. Burrill B. Crohn, “who first described the disease in 1932 along with colleagues Dr. Leon Ginzburg and Dr. Gordon D. Oppenheimer.” (Foundation, 2015) Konkel (2015) refers to this disease as belonging “to a group of conditions called inflammatory bowel diseases (IBD)” (Konkel, 2015) CD is
Crohn’s disease is a kind of inflammatory bowel disease primarily affecting the ileum and colon. It was first defined in detail in a paper by Burrill B. Crohn and two colleagues, where it was differentiated from other generic bowel diseases. Although they proposed the name “regional ileitis”, the popularity of the article lead to the adoption of Crohn’s name as association.
To stabilize the structure, the negative bromide was introduced via backside attack and made an anti product.
Diacerein inhibits IL-1 synthesis and release in vitro and modulates IL- 1induced activities. Diacerein also have been shown disease modifying effect in experimental models of osteoarthritis and in human subjects with finger joint and knee osteoarthritis. IL-1 plays a important role in cartilage destruction and osteoarthritis pathophysiology. IL-1 also increase release of prostaglandin E2, IL-6, IL-8 in human osteoarthritis chondrocytes, and promotes expression of inducible nitric oxide synthase which promote joint degradation. Therefore by inhibiting IL-1 diacerein retards all OA pathological prepossess.
These sequences are sourced from Subunit 1 of the Cytochrome Oxidase gene in the Mitochondria.
For the second part of the experiment, one had to use the knowledge learn from viewing protein molecules in FirstGlance in Jmol to analyze the protein PDB ID: 4EEY. The analysis of this protein was done using the RSCB protein data bank (PDB) at (http://www.rcsb.org/pdb/home/home.do).2